Abstracts on heart failure research are invited in the following categories:

• Advanced Heart Failure, Durable Mechanical Circulatory Support
• Cardiogenic Shock, Temporary Mechanical Circulatory Support, and Critical Care Cardiology
• HFrEF/HFimpEF/HFmrEF Clinical Care, Management Strategies, New Interventions
• Transplant
• Caregiving, Patient Perspectives, Palliation and End of Life
• HFpEF Clinical Care, Management Strategies, New Interventions
• Hospitalized HF, Readmissions
• Nutrition, Metabolism, Obesity, and Exercise
• Pulmonary Hypertension and Right Heart Failure
• Valvular Disease
• Business of Heart Failure (Health Policy and Economics)
• Comorbidities (Kidney Disease, Diabetes, Lung Disease, Sleep Disorders, Anemia, COVID-19)
• Epidemiology and Global Heart Failure
• Non-MCS Heart Failure Devices (Remote Monitoring, EP Devices, Structural, Other Innovations)
• Population Health, Social Determinants of Health and Disparities of Care, Outcomes Research
• Preventive Cardiology
• Quality Improvement and Implementation
• Basic and Translational Science, Biomarkers, -Omics, Precision Medicine
• Genetics, Inherited Cardiomyopathies, HCM
• Infiltrative Cardiomyopathies (Sarcoidosis, Amyloidosis) and Myocarditis
• Leadership and Education
• Specialty Populations (Cardio-Oncology, Cardio-OB, Geriatric)
• Case Report/Case Study

*Note: Case Studies/Reports and Performance Improvement Initiative abstracts are not eligible for the JNC or Nursing Investigator awards. Case Studies/Reports should indicate if they wish to be considered for the special Case Competition. Any case reports not selected for the Case Competition will be considered for general abstract sessions. More information about the Case Competition and what it entails can be found on the HFSA site here.

Writing an Abstract

• Title: Make the title dynamic and conclusive, rather than descriptive
• Structure: A well-written abstract typically has the following identified sections: Introduction, Hypothesis, Methods, Results and Conclusions.
• Category: Check submission category carefully to assure proper consideration.
• Length: Maximum length is 2800 characters, including tables and graphs.

Title

An abstract must have a short, specific title (no abbreviations) that clearly indicates the nature of the investigation. Make the title dynamic and conclusive, rather than descriptive.

Text

• Briefly describe the objectives of the study unless they are contained in the title. If applicable, include a brief statement of methods. State findings in sufficient detail to support conclusions.   Abstracts should not describe research in which the chemical identity or source of the reagent   is proprietary or cannot be revealed.
• Use generic names wherever possible. Use trade names only when necessary.
• Avoid beginning sentences with numerals.
• Standard abbreviations may be used without definition. Nonstandard abbreviations should be   placed in parentheses after the first use of the word or phrase abbreviated.
• No references, credits or grant support should be included in the abstract.
• No identifying information about patients participating in a study or trial should be used.
• Proofread abstracts carefully to avoid errors before submission. No corrections will be allowed   or made once abstract has been submitted.

Abstract Contents

The size limit for an abstract 2,800 characters, including characters in the following: abstract title, body, and table(s) and image(s). Adding a Table/Image removes 320 characters from your character limit. Abstract authors and institutions do not count towards the character limit.

Abstract Keywords

Authors will select a general category for their abstract topic, and will also have the opportunity to select specific keywords for their abstracts. Please select the most accurate keyword for your abstract, to help organization and categorizing.

HFSA will be utilizing ePosters at ASM 2026. An ePoster is a digital presentation of a poster. There will be no hardcopy or paper posters. Attendees will be able to view ePosters in the ePoster Hub in the Exhibit Hall during the Annual Scientific Meeting, regardless of day and time of presentations. ePoster presenters will have their posters featured for a 30 minute slot, and are requested to be present by their poster during that time slot to engage in informal Q&A with any viewers.

Presenting authors of accepted abstracts will be required to register for the meeting. After acceptance and confirmation, an email will be send to notify you of your abstract presentation time and session in late June-early July.

You may use your own poster template or one of our PowerPoint templates. Template use is not required; it is simply provided for reference. Templates will be linked here at a later date.

• Preferred file format: PDF file or PowerPoint
• Orientation: Landscape format (ratio 16/9 Ratio)

During the meeting, you will be requested to attend your scheduled ePoster presentation for a duration of 30 minutes for informal ePoster question and answer from any viewing participants. 

You will be able to add audio narration to your ePoster sections, during the final review step.

Author Names

If an author’s name appears on more than one abstract, it must be identical on each abstract. The submitting author is designated as the presenting or primary author – the presenting   author is shown in green in Oasis. The senior author must always be listed last.

Abstract Data

1. The Heart Failure Society of America is a forum for presentation of novel research findings. Therefore, work covered by the abstract must not have been published as a manuscript or abstract prior to March 23, 2026.
2. Abstract data may not be presented at a national meeting or world congress in the United States prior to July 1, 2026.
3. Data should not be “split” to create several abstracts from one. Splitting will result in reduced scores for related abstracts.
4. Abstracts containing identical or nearly identical data submitted from the same institution or individual will be disqualified.
5. Informed consent: any studies involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 1996;14:103) and must meet all of the requirements governing informed consent of the country in which the study was performed. Any procedures performed must meet with prevailing ethical standards.
6. Use of Animals: All studies involving the use of animals must conform with the 1991 revision of “Guiding Principles in the Care and Use of Animals” (American Physiological Association).

Award Competitions

If submitting for an award competition or the special case competition case session, please check the appropriate box and provide required information. Abstracts submitted for award competition cannot be submitted as ePoster Presentation Only. An Oral Presentation will be required.

Co-Author Approval

The submitting author must verify that all co-authors have read and approved the abstract submission.

Disclosure Form

A disclosure form identifying commercial relationships must be completed online by the submitting author. The submitting author must have a current disclosure status before March 23, 2026, 11:59 PM ET or the abstract will remain incomplete and will not be reviewed. If the abstract is accepted and further disclosure information is required, the submitting or presenting author will take responsibility for adding and confirming all necessary information for all listed authors.

The submitting author must verify that no relevant COIs exist for co-authors listed on the abstract.

Abstract Submission Fee

The abstract submission fee is $35.00 (USD) for non-members. This non-refundable fee applies to a non-member who is the presenting author on an abstract. Email info@hfsa.org if you are unsure of your membership status or number.

Presenting authors who are members of the Society in good standing (membership dues current) do not need to pay the abstract submission fee. Note: If the presenting author is not a member, or has a membership application pending and not approved at the time of submission, the abstract submission fee will need to be paid. Payment must be submitted with your abstract submission. The Society accepts MasterCard, Visa, and American Express.

Note: Your abstract is not complete until the payment is processed. However, payment alone does not make your abstract complete. All other steps of the abstract submission must be completed as well.
 

Abstract Submissions by Industry

Abstract submissions from industry are allowed. Submissions must focus on science and research, not on specific products or services. Abstract presentations cannot be sales presentations or endorsements for products or services.

Abstract Withdrawal

Withdrawal of accepted abstracts must be received in writing (via email) by HFSA no later than August 3, 2026 to avoid publication in the Journal of Cardiac Failure electronic supplemental issue.

Electronic Submissions

The submission site works optimally with Microsoft Internet Explorer 7, Safari version 3.2 or higher, or Mozilla Firefox version 6.0 or higher (some aspects may not work so well with Chrome). The Call for Abstracts screen provides links to this free software. The site is available 24 hours a day. Multiple authors can easily review or work on the abstract from different locations. The site supports graphic images, tables (with special characters/symbols), Greek characters and special symbols.

The 2026 HFSA Annual Scientific Meeting will feature ePosters, oral abstract presentations, oral presentation award sessions, and a special electronic supplemental Issue of the Journal of Cardiac Failure with published abstracts.

Acceptance

1. All abstracts submitted must comply with the guidelines to be considered for acceptance.
2. Abstract grading is blinded. Abstracts are selected on the basis of scientific merit.
3. Acceptance notifications will be sent in June 2026.
4. Authors will be expected to register for the meeting and present their posters. A registration will be required to present.
5. Authors will receive technical guidelines on how to prepare a PDF document to display properly as an ePoster, and how to prepare an audio narrative.
6. Abstracts accepted are embargoed (see embargo policy) for release until the time of presentation at the Heart Failure Society of America’s Scientific Meeting.
7. Abstracts accepted for presentation will be published in an electronic supplemental issue of the Journal of Cardiac Failure. Authors whose abstracts are accepted give HFSA permission and authority to submit and publish their abstract, without compensation, in the Journal of Cardiac Failure.
8. HFSA reserves the right to all video or audio recordings of presentations at the 2026 Annual Scientific Meeting
9. There is a $35.00 (USD) fee for each abstract submitted by a non-member. This $35 fee applies to a non-member who is the presenting author on an abstract. HFSA members are not required to pay an abstract submission fee. Please Email info@hfsa.org if you are unsure of your membership status or number.

Author’s Conflict

If the abstract is selected, an author is required to present their research at the annual meeting to be published in JCF. If the original designated presenting author has a conflict, they can allow a co-author to present in their place, but will need to notify us in advance. Notification letters will go out in June. Authors will have approximately 2 weeks to accept or decline their invitation to present. If they decline, their abstract will not be published in JCF or presented at the meeting. If no response is received, the abstract will be automatically set as declined.

Abstracts selected for oral presentation in an award session such as the JNC or Nursing Investigator Awards will receive special notification letters with additional information on their schedule and requirements.

Abstracts selected for oral presentation in an oral abstract session will receive special notification letters with additional information on their schedule and requirements.

Abstracts selected for oral presentation in the Case Competition session will receive special notification letters with additional information on their schedule and requirements.

Once your abstract decision notification has been sent, you can contact aleong@hfsa.org to confirm if an abstract has been accepted or confirmed. You can check this status either yourself or for an abstract where you are listed as an author.

All accepted non-late-breaking general abstracts are embargoed for release until the start of the Heart Failure Society of America’s Annual Scientific Meeting. 

At the start of the meeting and anytime thereafter, researchers, authors, universities, medical institutions and health care organizations involved in the study may issue press releases and announcements to the public and media. 

Researchers, authors, universities, medical institutions and health care organizations that are involved in a study may distribute their own embargoed news release 2 business days prior to the embargo, and authors of studies and representatives from the institution may conduct embargoed media interviews during the 2-day pre-embargo period with journalists who agree to honor the embargo. 

Promotional media activities (such as media briefings/news conferences, satellite media tours, corporate receptions or investigator meetings) may not be held until after the embargo lifts. You may conduct one-on-one embargoed media interviews as long as the reporter agrees to abide by the embargo policy.  

Failure to honor this embargo policy may jeopardize future acceptance of clinical trials and presentations at ASM. 

Sharing Your News with ASM Registered Media 
To ensure that your release is brought to the attention of registered media and included in communications to registered press, please send your news release for an abstract being presented at ASM to marketing@hfsa.org. In the body of the email, please include the following:  

• The full name of the abstract; 
• The first and last authors’ names as they are listed on the abstract; and 
• If it is being published in a scientific journal, please include the name of the journal where it is being published or the name of the meeting where it will be presented, and the date/time of the anticipated publication.